Investigating how a specific protein affects brain cells in Alzheimer's disease
GPCR-dependent microglial function in Alzheimer's disease
['FUNDING_CAREER'] · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · NIH-10979161
This study is looking at how a protein called GPR56 in brain cells might affect the progression of Alzheimer's disease, using a special mouse model to see how these cells respond to changes related to the disease, which could help find new treatments for patients.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (nih funded) |
| Locations | 1 site (SAN FRANCISCO, UNITED STATES) |
| Trial ID | NIH-10979161 on ClinicalTrials.gov |
What this research studies
This research focuses on understanding the role of GPR56, a protein found in microglial cells, in the progression of Alzheimer's disease (AD). By using a new mouse model, the study aims to explore how changes in microglial function may influence the development of AD pathology, particularly in relation to amyloid plaques. The research will involve examining the behavior of these brain cells in response to Alzheimer's-related changes, which could provide insights into potential therapeutic targets. Patients may benefit from findings that could lead to new treatments aimed at modifying microglial activity in AD.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research would include individuals at risk for Alzheimer's disease or those in the early stages of the condition.
Not a fit: Patients with advanced Alzheimer's disease or those with other forms of dementia unrelated to Alzheimer's may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that modify microglial function to slow or prevent the progression of Alzheimer's disease.
How similar studies have performed: Previous research has indicated that targeting microglial function may hold promise for Alzheimer's treatment, suggesting that this approach could be a meaningful advancement in the field.
Where this research is happening
SAN FRANCISCO, UNITED STATES
- UNIVERSITY OF CALIFORNIA, SAN FRANCISCO — SAN FRANCISCO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHU, BEIKA — UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- Study coordinator: ZHU, BEIKA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia